JAK1 and lung cancer: Our studies with the OncoImmune PPI and HTiP approaches uncovered IAP and IAP-regulated JAK1-STING innate immunity pathway as an immune-dependent vulnerability in LKB1 mutated lung cancer cells for overcoming the immunotherapy resistance.